CAJ | 학술논문

bcr-abl阴性的骨髓增殖性肿瘤(MPN)包括真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF).随着JAK2 V617F基因突变在MPN患者中的发现,一系列针对该突变的小分子靶向药物被研发,其中通过COMFORT-Ⅰ和COMFORT-Ⅱ等试验研究的JAK1/2抑制剂芦可替尼(ruxolitinib)已经被美国食品和药品管理局(FDA)和欧洲药品管理局(EMA)批准应用于中晚期PMF患者和羟基脲耐药或不耐受PV患者的治疗,给MPN患者带来了新的希望.
bcr-abl음성적골수증식성종류(MPN)포괄진성홍세포증다증(PV)、원발성혈소판증다증(ET)화원발성골수섬유화(PMF).수착JAK2 V617F기인돌변재MPN환자중적발현,일계렬침대해돌변적소분자파향약물피연발,기중통과COMFORT-Ⅰ화COMFORT-Ⅱ등시험연구적JAK1/2억제제호가체니(ruxolitinib)이경피미국식품화약품관리국(FDA)화구주약품관리국(EMA)비준응용우중만기PMF환자화간기뇨내약혹불내수PV환자적치료,급MPN환자대래료신적희망.
The bcr-abl negative myeloproliferative neoplasms (MPN) include polycythemia vera (PV),essential thrombocythemia (ET) and primary myelofibrosis (PMF).Along with the detecting of JAK2 V617F gene mutation in MPN patients,a series of small molecules drugs that targeted to the mutation have been investigated in clinical trials.Ruxolitinib is the inhibitor of JAK1/2,which has been proved by USA Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to treat patients with intermediate-2 or high-risk PMF or post-PV MF or post-ET MF and PV patients who are intolerant or resistant to hydroxycarbamide,attributed to a number of clinical trials,especially in COMFORT-Ⅰ and COMFORT-Ⅱ.As a result,the MPN patients have new hope for the treatment.